Literature DB >> 22772389

The future of HIV treatment.

Martin S Hirsch1, Daniel R Kuritzkes.   

Abstract

Antiretroviral therapy has transformed the management of HIV-infected individuals over the past quarter century. However, important challenges remain. These include attempts to eradicate HIV from reservoirs within the body, thereby eliminating the need for lifetime therapy. In addition, improvements in drug development, clinical trial, and regulatory pathways are necessary to expeditiously evaluate novel therapeutic regimens and strategies. Antiretroviral drug scarcity remains a major problem in underserved populations worldwide, and partnerships among pharmaceutical companies, academic investigators, and both governmental and nongovernmental agencies are necessary to improve access to these life-saving regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772389      PMCID: PMC3404730          DOI: 10.1097/QAI.0b013e318258bc9f

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

Review 1.  Novel clinical trial designs for the development of new antiretroviral agents.

Authors:  Nina Mani; Jeffrey Murray; Roy M Gulick; Filip Josephson; Veronica Miller; Peter Miele; Jur Strobos; Kimberly Struble
Journal:  AIDS       Date:  2012-05-15       Impact factor: 4.177

Review 2.  The challenge of finding a cure for HIV infection.

Authors:  Douglas D Richman; David M Margolis; Martin Delaney; Warner C Greene; Daria Hazuda; Roger J Pomerantz
Journal:  Science       Date:  2009-03-06       Impact factor: 47.728

3.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

4.  Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Kathleen L Vincent; Massoud Motamedi; David R Friend; Meredith R Clark; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

Authors:  Kristina Allers; Gero Hütter; Jörg Hofmann; Christoph Loddenkemper; Kathrin Rieger; Eckhard Thiel; Thomas Schneider
Journal:  Blood       Date:  2010-12-08       Impact factor: 22.113

6.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

Review 7.  Histone deacetylase inhibitors and HIV latency.

Authors:  David M Margolis
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

8.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

9.  Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

Authors:  Gerben van 't Klooster; Eva Hoeben; Herman Borghys; Adriana Looszova; Marie-Paule Bouche; Frans van Velsen; Lieven Baert
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

10.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

Authors:  Liang Shan; Kai Deng; Neeta S Shroff; Christine M Durand; S Alireza Rabi; Hung-Chih Yang; Hao Zhang; Joseph B Margolick; Joel N Blankson; Robert F Siliciano
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

  10 in total
  1 in total

Review 1.  Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.

Authors:  Opass Putcharoen; Tanya Do; Anchalee Avihingsanon; Kiat Ruxrungtham
Journal:  Drug Des Devel Ther       Date:  2015-10-23       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.